Overview

Antithrombin III in Infectious Disease Caused by COVID-19

Status:
Recruiting
Trial end date:
2021-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
Phase:
Phase 2
Details
Lead Sponsor:
Enrique Ginzburg
Collaborator:
Grifols Biologicals, LLC
Treatments:
Antithrombin III
Antithrombins